Ipsen
IPN · Euronext Paris
Public Market Listing
Live quotes, historical charts, and market capitalization for Ipsen are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | MET / VEGFR / AXL / RET (multi-kinase)Small molecule | Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer Clear Cell Renal Cell Carcinoma | |
Elafibranor(Iqirvo) | Approved | PPAR-alpha/PPAR-deltaSmall molecule | Cholestatic Liver Disease Primary Biliary Cholangitis |
| Approved | Kinase InhibitorSmall molecule | Glioma |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
2029 (1)
May 2029 (1)
What to watch
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.